Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00869323 · ClinicalTrials.gov registry record · Phase 2
Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT00869323 is a Phase 2 study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 3 participants.
The verdict
NCT00869323, a Phase 2 study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Monoclonal antibodies, such as rituximab, can block cancer cell growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving bortezomib together with rituximab may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving bortezomib together with rituximab works in treating patients with post-transplant lymphoproliferative disorders.
Interventions
- BIOLOGICAL rituximab
- DRUG bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2009-03 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00869323
The ClinicalTrials.gov registry entry for NCT00869323 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which rituximab is the first listed.
NCT00869323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00869323 about?
NCT00869323 is a clinical study titled "Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders". RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Monoclonal antibodies, such as rituximab, can block cancer cell growth in different ways. Some block the ability of cancer cells to grow and spre...
What is the current status of trial NCT00869323?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2009-03. Estimated completion is 2016-12.
What interventions are being tested in trial NCT00869323?
The interventions under investigation include: rituximab (BIOLOGICAL), bortezomib (DRUG).
Who is sponsoring clinical trial NCT00869323?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.